Oxford Asset Management LLP Acquires Shares of 16,210 GoodRx Holdings, Inc. (NASDAQ:GDRX)

Oxford Asset Management LLP bought a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 16,210 shares of the company’s stock, valued at approximately $75,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GDRX. Vanguard Group Inc. increased its position in GoodRx by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 8,373,039 shares of the company’s stock valued at $38,935,000 after acquiring an additional 460,753 shares in the last quarter. Dimensional Fund Advisors LP raised its position in GoodRx by 22.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company’s stock worth $9,264,000 after purchasing an additional 369,553 shares during the last quarter. Clearbridge Investments LLC bought a new position in GoodRx in the 4th quarter valued at $5,863,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of GoodRx by 38.7% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,228,836 shares of the company’s stock valued at $5,714,000 after buying an additional 342,781 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of GoodRx by 9.1% during the fourth quarter. Geode Capital Management LLC now owns 1,071,761 shares of the company’s stock worth $4,986,000 after acquiring an additional 89,032 shares during the last quarter. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Stock Down 1.1 %

NASDAQ:GDRX opened at $4.63 on Tuesday. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -154.33, a PEG ratio of 2.46 and a beta of 1.25. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The stock has a 50-day moving average price of $4.57 and a two-hundred day moving average price of $4.87. GoodRx Holdings, Inc. has a 1 year low of $3.82 and a 1 year high of $9.26.

Analyst Ratings Changes

GDRX has been the topic of several recent research reports. Citigroup decreased their price target on GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a report on Friday, January 10th. KeyCorp lowered their price target on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Truist Financial cut their price objective on shares of GoodRx from $6.50 to $5.50 and set a “hold” rating on the stock in a report on Thursday, April 10th. Finally, Wells Fargo & Company lowered their target price on shares of GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $7.93.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.